Business · 08/06/2022
FDA Renews Pulmonary-Allergy Drugs Advisory Committee for 2 Years
The FDA has renewed the Pulmonary-Allergy Drugs Advisory Committee for an additional 2 years, with the new charter set to expire on May 30, 2024.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →